The UC Hematologic Malignancies Consortium (UCHMC) is a collaboration of academic clinicians across UC’s five NCI-designated Comprehensive Cancer Centers and UCSF Fresno, and its mission is to conduct clinical research on rare blood cancers with enough patients to make a difference in the science that can lead to precision treatment.
UCHMC Clinical Trials
The following UCHMC-initiated studies are now underway. Click the links to learn more about each clinical trial including eligibility requirements.
Leukemia
Frontline Ruxolitinib with De-Intensified HLH-94 for Adult Hemophagocytic Lymphohistiocytosis (HLH): A Multicenter, Single-Arm Phase 2 Study
Locations: UC Davis Comprehensive Cancer Center, UC Irvine Chao Family Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center
A Phase 2 Study of Olutasidenib Maintenance After HMA-Ven for IDH1-Mutated AML
Locations: UC Davis Comprehensive Cancer Center
Current leukemia clinical trials across the UC system
Lymphoma
A Study of Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Locations: UC Davis Comprehensive Cancer Center, UC Irvine Chao Family Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Locations: UC Davis Comprehensive Cancer Center, UCLA Jonsson Comprehensive Cancer Center
A phase II study of epcoritamab (epco) plus physician's choice of platinum-containing chemotherapy preautologous hematopoietic cell transplantation (autoHCT) followed by post-autoHCT epco consolidation/ maintenance in relapsed/ refractory large B- cell lymphoma (R/R DLBCL).
Location: UC Davis Comprehensive Cancer Center
A phase 1 study of odronextamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) before and after chimeric antigen receptor (CAR) T-cell therapy
Location: UC Davis Comprehensive Cancer Center
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
Location: UC Davis Comprehensive Cancer Center
A Phase 1b study of glofitamab with pirtobrutinib for relapsed or refractory mantle cell lymphoma
Location: UC Davis Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center
Current lymphoma clinical trials across the UC system
Multiple Myeloma
Talquetamab + Iberdomide *(1.2 but can go down to 1 if there are issues)+ Dex (IIT)
Locations: UCSF Helen Diller Family Comprehensive Cancer Center
Current multiple myeloma clinical trials across the UC system
Funding Opportunities
The UC Hematologic Malignancies Consortium supports projects that encourage collaboration among UC campuses. For additional information, contact Jesika Reiner.
About us
The UCHMC aims to make treatment of rare blood cancers more accessible for a larger and more diverse patient population, through the expansion of multi-site clinical trials led by physician scientists across the UC system.
Leadership
Matthew Joseph Wieduwilt, M.D., Ph.D. (Chair)
UC Davis Comprehensive Cancer Center
Joseph Tuscano, M.D.
UC Irvine Chao Family Comprehensive Cancer Center
Deepa Jeyakumar, M.D.
UCLA Jonsson Comprehensive Cancer Center
Gary Schiller, M.D.
UC San Diego Moores Cancer Center
Erin Reid, M.D.
UCSF Helen Diller Family Comprehensive Cancer Center
Michael Spinner, M.D.
UCSF Fresno
Haifaa Abdulhaq, M.D.
Working Groups and Disease Teams
- Tissue Core and Database
- Multiple Myeloma
- Lymphoma (Including CLL)
- Acute Leukemia/MDS/MPN
- Hematopoietic Stem Cell Transplantation and Cellular Therapy